Andersons pediatric cardiology 153

Cardiac disease burden and risk of mortality in hospitalized muscular dystrophy patients Pediatr Cardiol 2016;37:1290–1296 239 Bushby K, Finkel R, Birnkrant DJ, et al Diagnosis and management of Duchenne muscular dystrophy, part 2: Implementation of multidisciplinary care Lancet Neurol 2010;9:177–189 240 Starc JJ, Moore RA, Rattan MS, et al Elevated myocardial extracellular volume fraction in Duchenne muscular dystrophy Pediatr Cardiol 2017 241 Hor KN, Taylor MD, Al-Khalidi HR, et al Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: Effect of age and left ventricular systolic function J Cardiovasc Magn Reson 2013;15:107 242 Mavrogeni S, Bratis K, Papavasiliou A, et al CMR detects subclinical cardiomyopathy in mother-carriers of Duchenne and Becker muscular dystrophy JACC Cardiovasc Imaging 2013;6:526–528 243 Lang SM, Shugh S, Mazur W, et al Myocardial fibrosis and left ventricular dysfunction in Duchenne muscular dystrophy carriers using cardiac magnetic resonance imaging Pediatr Cardiol 2015;36:1495–1501 244 American Academy of Pediatrics Section on Cardiology and Cardiac Surgery Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy Pediatrics 2005;116:1569–1573 245 Young MJ Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation Curr Opin Nephrol Hypertens 2008;17:174–180 246 Raman SV, Hor KN, Mazur W, et al Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: A randomised, double-blind, placebocontrolled trial Lancet Neurol 2015;14:153– 161 247 Raman SV, Hor KN, Mazur W, et al Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: Results of a two-year open-label extension trial Orphanet J Rare Dis 2017;12:39 248 Heier CR, Damsker JM, Yu Q, et al VBP15, a novel anti-inflammatory and membranestabilizer, improves muscular dystrophy without side effects EMBO Mol Med 2013;5:1569– 1585 249 Kornegay JN The golden retriever model of Duchenne muscular dystrophy Skelet Muscle 2017;7:9 250 Tinsley JM, Fairclough RJ, Storer R, et al Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse PLoS ONE 2011;6:e19189 251 Ricotti V, Spinty S, Roper H, et al Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with Duchenne muscular dystrophy PLoS ONE 2016;11:e0152840 252 Swaggart KA, McNally EM Modifiers of heart and muscle function: Where genetics meets physiology Exp Physiol 2014;99:621–626 253 Vieira NM, Spinazzola JM, Alexander MS, et al Repression of phosphatidylinositol transfer protein alpha ameliorates the pathology of Duchenne muscular dystrophy Proc Natl Acad Sci USA 2017;114:6080–6085 254 Aartsma-Rus A, Straub V, Hemmings R, et al Development of exon skipping therapies for Duchenne muscular dystrophy: A critical review and a perspective on the outstanding issues Nucleic Acid Ther 2017 255 Charron P, Villard E, Sebillon P, et al Danon's ... American Academy of Pediatrics Section on Cardiology and Cardiac Surgery Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy Pediatrics 2005;116:1569–1573... C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with Duchenne muscular dystrophy PLoS ONE 2016;11:e0152840 252 Swaggart KA, McNally EM